3 articles tagged "targeted therapy"
A multicenter randomized controlled trial demonstrates notable efficacy outcomes for dual-targeted therapy in EGFR-mutated advanced NSCLC, though several methodological considerations warrant examination.
A first-in-class small-molecule inverse agonist of peroxisome proliferator-activated receptor gamma achieved objective responses in 17.5% of patients with urothelial carcinoma in a phase 1 dose-escalation study. The agent exhibited acceptable tolerability with grade 3 or higher adverse events primarily consisting of hematologic toxicities.
A phase I dose-escalation study of rezatapopt demonstrated preliminary antitumor activity in patients with TP53 Y220C-mutated solid tumors, representing the first clinical validation of mutation-specific p53 reactivation therapy.